Where will tomorrow’s workforce come from? PART 3: Innovation in staff sourcing, training and retention - what works and what doesn’t?

Published: 13 June 2022
Sven Kili, Michael Lehmicke, Qasim Rafiq, Emily Hopewell, James Miskin, Frank Barry, Parviz Shamlou

Welcome to a 4-part series exploring a question that the entire cell and gene therapy community is struggling with at the moment: “Where will tomorrow’s workforce come from?”

The cell and gene therapy field has been advancing at a breakneck speed for the best part of a decade now, fuelled by long-awaited clinical successes, commercial breakthroughs, and a related startling increase in activity from both investors and big pharma. But with this relentless pace of growth and innovation comes the fundamental challenge of developing a sufficiently large and skilled workforce to support and maintain the sector.

In Part 2, we looked predominantly at how the educational system is evolving to meet the specific training and skills requirements of the burgeoning advanced therapies field. In this third PART, we turn the spotlight onto the cell and gene therapy industry and how it is approaching staff development and retention – a crucial area that has been made all the more challenging by the current high level of competition for talent in the field, as well as the evolving mindset of workers relating to their career development and pathway that has been wrought by the Covid-19 pandemic, amongst other things.

So what are the keys to ensuring a cell or gene therapy company can keep hold of its brightest stars and help them to flourish and grow? Hear the thoughts of Sven Kili, James Miskin, Michael Lehmicke, Qasim Rafiq and Emily Hopewell.